HK1087708A1 - Escitalopram hydrobromide and method for the preparation thereof - Google Patents
Escitalopram hydrobromide and method for the preparation thereofInfo
- Publication number
- HK1087708A1 HK1087708A1 HK06108012A HK06108012A HK1087708A1 HK 1087708 A1 HK1087708 A1 HK 1087708A1 HK 06108012 A HK06108012 A HK 06108012A HK 06108012 A HK06108012 A HK 06108012A HK 1087708 A1 HK1087708 A1 HK 1087708A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preparation
- escitalopram hydrobromide
- escitalopram
- hydrobromide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200202005 | 2002-12-23 | ||
PCT/DK2003/000902 WO2004056791A1 (en) | 2002-12-23 | 2003-12-18 | Escitalopram hydrobromide and a method for the preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1087708A1 true HK1087708A1 (en) | 2006-10-20 |
Family
ID=32668635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06108012A HK1087708A1 (en) | 2002-12-23 | 2006-07-18 | Escitalopram hydrobromide and method for the preparation thereof |
Country Status (33)
Country | Link |
---|---|
US (1) | US20040167209A1 (de) |
EP (1) | EP1578738B1 (de) |
JP (2) | JP4658613B2 (de) |
KR (1) | KR20050086933A (de) |
CN (1) | CN100349885C (de) |
AR (1) | AR042652A1 (de) |
AT (1) | ATE388947T1 (de) |
AU (1) | AU2003287919B2 (de) |
BR (1) | BR0317623A (de) |
CA (1) | CA2511142A1 (de) |
CY (1) | CY1107451T1 (de) |
DE (1) | DE60319739T2 (de) |
DK (1) | DK1578738T3 (de) |
EA (1) | EA013116B1 (de) |
EG (1) | EG24729A (de) |
ES (1) | ES2298595T3 (de) |
HK (1) | HK1087708A1 (de) |
IL (1) | IL169125A0 (de) |
IS (1) | IS2654B (de) |
ME (1) | MEP5808A (de) |
MX (1) | MXPA05005772A (de) |
MY (1) | MY135468A (de) |
NO (1) | NO20053595L (de) |
NZ (1) | NZ540281A (de) |
PE (1) | PE20040924A1 (de) |
PL (1) | PL378275A1 (de) |
PT (1) | PT1578738E (de) |
RS (1) | RS51092B (de) |
TW (1) | TW200501943A (de) |
UA (1) | UA80170C2 (de) |
UY (1) | UY28148A1 (de) |
WO (1) | WO2004056791A1 (de) |
ZA (1) | ZA200504109B (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
AU2003287919B2 (en) * | 2002-12-23 | 2009-11-12 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
EA200601641A1 (ru) * | 2004-03-05 | 2006-12-29 | Х. Лундбекк А/С | Кристаллическая композиция, содержащая оксалат эсциталопрама |
US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
TWI358407B (en) * | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
WO2007053796A2 (en) * | 2005-10-14 | 2007-05-10 | Forest Laboratories, Inc. | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
CA2626025A1 (en) * | 2005-10-14 | 2007-04-26 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
WO2008007691A1 (fr) * | 2006-07-11 | 2008-01-17 | Mitsubishi Tanabe Pharma Corporation | Sels de composé de morpholine |
WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
FR3006594A1 (fr) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire |
CN108976188B (zh) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | 一种艾司西酞普兰双羟萘酸盐新的制备方法 |
PL3694843T3 (pl) | 2017-10-09 | 2022-06-20 | Hasleton, Mark | Nowa sól i nowe stałe postacie escitalopramu |
US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US34712A (en) * | 1862-03-18 | James h | ||
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
IL142346A0 (en) * | 1998-10-20 | 2002-03-10 | Lundbeck & Co As H | Method for the preparation of citalopram |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
DK1298124T3 (da) * | 1999-10-25 | 2007-07-09 | Lundbeck & Co As H | Fremgangsmåde til fremstilling af citalopram |
US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
JP2002020379A (ja) * | 2000-05-02 | 2002-01-23 | Sumika Fine Chemicals Co Ltd | シタロプラム臭化水素酸塩の結晶およびその結晶化方法 |
CA2353693C (en) * | 2000-08-10 | 2003-07-22 | H. Lundbeck A/S | Pharmaceutical composition containing citalopram |
US6960673B2 (en) * | 2000-12-04 | 2005-11-01 | Westfalia Separator Ag | Method for pretreating crude oils and raw fats for the production of fatty acid esters |
MEP5908A (xx) * | 2001-05-01 | 2010-02-10 | Lundbeck & Co As H | Upotreba enantiomerno čistog escitaloprama |
AR034612A1 (es) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
AU2003287919B2 (en) * | 2002-12-23 | 2009-11-12 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
US20050174782A1 (en) * | 2003-03-25 | 2005-08-11 | Chapman Leonard T. | Flashlight |
-
2003
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 EP EP03779759A patent/EP1578738B1/de not_active Expired - Lifetime
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Application Discontinuation
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en active IP Right Grant
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
-
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
-
2006
- 2006-07-18 HK HK06108012A patent/HK1087708A1/xx not_active IP Right Cessation
-
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
-
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1087708A1 (en) | Escitalopram hydrobromide and method for the preparation thereof | |
HK1167332A1 (en) | Pharmaceutical composition, use thereof and method for making the same | |
WO2002015264A3 (de) | Verkapseltes organisch-elektronisches bauteil, verfahren zu seiner herstellung und seine verwendung | |
AU2003222408A1 (en) | Garment and method for producing the same | |
HK1082520A1 (en) | T cell vaccine and the method for preparing the same | |
AU2003297037A8 (en) | Illuminant and method | |
IL153864A0 (en) | Cyclic polyamine compounds and methods for the preparation thereof | |
AU2003271224A8 (en) | Fibrous nano-carbon and preparation method thereof | |
EG24579A (en) | Herbicide composition and weed-controlling method using the same | |
EP1521791A4 (de) | Auf norbornenester basierendes polymerisat und verfahren zu seiner herstellung | |
IL159183A0 (en) | Method for the preparation of escitalopram | |
AU2001251083A1 (en) | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists | |
IL161714A0 (en) | Method for the preparation of escitalopram | |
AU2003296369A8 (en) | Imminoamines and preparation thereof | |
EP1537083A4 (de) | S-(-)-amlodipinnicotinat und verfahren zu dessen herstellung | |
EP1581004A4 (de) | Codierer und verfahren dafür | |
AU2003281698A8 (en) | 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof | |
ZA200307846B (en) | Latex and its preparation. | |
EP1355548A4 (de) | Anzugeinlagestoff und verfahren zur herstellung des anzugs unter verwendung desselben | |
EP1517879A4 (de) | Aminoalkylphenole und verfahren zu deren verwendung und herstellung | |
AU2003297833A8 (en) | Canine rankl and methods for preparing and using the same | |
HK1065900A1 (en) | Tf-determination device, and tf-determination method | |
SI1578738T1 (sl) | Escitalopram hidrobromid in postopek za pripravo le-tega | |
IL165030A0 (en) | Compound and processes for the preparation and usethereof | |
GB0107033D0 (en) | Method and composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20121218 |